Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL175333 | 0.93 | GRM5 (0.39) | GRM5DRD3DRD2GPR6 | |
| SCHEMBL17156974 | 0.82 | GRM5 (0.39) | GRM5DRD3DRD2GPR6 | |
| Cadaverine Tartrate SCHEMBL15736937 | 0.80 | HRH3 (0.40) | GRM5DRD3GPR6 | |
| SCHEMBL17156967 | 0.79 | HRH3 (0.42) | GRM5BRD4 | |
| SCHEMBL17156963 | 0.79 | GRM5 (0.48) | GRM5GPR6 | |
| Cadaverine Tartrate SCHEMBL164450 | 0.77 | GRM5 (0.38) | GRM5DRD3DRD2GPR6 | |
| SCHEMBL17156951 | 0.76 | GRM5 (0.51) | GRM5HDAC6 | |
| SCHEMBL17156958 | 0.76 | GRM5 (0.51) | GRM5HDAC6 | |
| SCHEMBL17156972 | 0.76 | GRM5 (0.49) | GRM5GPR6 | |
| SCHEMBL17156955 | 0.76 | GRM5 (0.50) | GRM5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | claimed |
| EP-2611444-B1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| US-8912179-B2 | Heterocyclyl compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-12-16 | — | — | US | disclosed |
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2611444-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029070-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148440-A1 | HETEROCYCLYL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | HRH3, HRH4, HRH1 | GRM5 171/4885DRD3 695/4885HPGD 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.